[go: up one dir, main page]

BRPI0909333A2 - derivado de espiroindolinona - Google Patents

derivado de espiroindolinona

Info

Publication number
BRPI0909333A2
BRPI0909333A2 BRPI0909333A BRPI0909333A BRPI0909333A2 BR PI0909333 A2 BRPI0909333 A2 BR PI0909333A2 BR PI0909333 A BRPI0909333 A BR PI0909333A BR PI0909333 A BRPI0909333 A BR PI0909333A BR PI0909333 A2 BRPI0909333 A2 BR PI0909333A2
Authority
BR
Brazil
Prior art keywords
spiroindolinone
derivative
spiroindolinone derivative
compounds
general formulas
Prior art date
Application number
BRPI0909333A
Other languages
English (en)
Inventor
Liu Jin-Jun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0909333A2 publication Critical patent/BRPI0909333A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/96Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0909333A 2008-03-19 2009-03-09 derivado de espiroindolinona BRPI0909333A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3779908P 2008-03-19 2008-03-19
PCT/EP2009/052737 WO2009115425A1 (en) 2008-03-19 2009-03-09 Spiroindolinone derivatives

Publications (1)

Publication Number Publication Date
BRPI0909333A2 true BRPI0909333A2 (pt) 2019-09-24

Family

ID=40595697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909333A BRPI0909333A2 (pt) 2008-03-19 2009-03-09 derivado de espiroindolinona

Country Status (13)

Country Link
US (1) US7723372B2 (pt)
EP (1) EP2265583B1 (pt)
JP (1) JP2011515353A (pt)
KR (1) KR20100121521A (pt)
CN (1) CN101977898A (pt)
AT (1) ATE528290T1 (pt)
AU (1) AU2009226866A1 (pt)
BR (1) BRPI0909333A2 (pt)
CA (1) CA2716979A1 (pt)
ES (1) ES2373857T3 (pt)
IL (1) IL208025A0 (pt)
MX (1) MX2010009927A (pt)
WO (1) WO2009115425A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2499145B1 (en) 2009-11-12 2016-01-27 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
CN103635473B (zh) 2011-03-10 2016-08-17 第一三共株式会社 二螺吡咯烷衍生物
CN102180828A (zh) * 2011-03-31 2011-09-14 四川大学 手性吲哚啉酮螺五环骨架化合物及不对称合成
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN103172555B (zh) * 2012-12-07 2014-07-09 山东绿叶制药有限公司 升麻中分离的吲哚生物碱化合物、制备方法及其用途
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
JP5248866B2 (ja) * 2005-02-22 2013-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Mdm2の小分子阻害剤およびその使用
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20080188506A1 (en) 2007-02-07 2008-08-07 Qingjie Ding Spiroindolinone derivatives
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives

Also Published As

Publication number Publication date
CA2716979A1 (en) 2009-09-24
US20090239889A1 (en) 2009-09-24
JP2011515353A (ja) 2011-05-19
US7723372B2 (en) 2010-05-25
MX2010009927A (es) 2010-09-30
ATE528290T1 (de) 2011-10-15
KR20100121521A (ko) 2010-11-17
WO2009115425A1 (en) 2009-09-24
ES2373857T3 (es) 2012-02-09
AU2009226866A1 (en) 2009-09-24
IL208025A0 (en) 2010-12-30
EP2265583B1 (en) 2011-10-12
CN101977898A (zh) 2011-02-16
EP2265583A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
BRPI0909333A2 (pt) derivado de espiroindolinona
MX2009004766A (es) Derivados de espiroindolinona.
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
BRPI0717266A2 (pt) Derivados de oxindol
CR20110099A (es) Pirrolidina-2-carboxamidas sustituidas
ATE495176T1 (de) Spiroindolinon-derivate
NO20083630L (no) Nye pyridinderivater
ATE483000T1 (de) Naphtalin-amidin-imide
UA107791C2 (en) Pesticidal compositions
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
UY30881A1 (es) Derivados de fenotiazina, procedimientos y su uso como productos farmacéuticos
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP10010722A (es) Compuestos orgánicos
LT3372281T (lt) Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
MY169043A (en) New dihydroquinoline-2-one derivatives
IN2012DN02487A (pt)
TR201808501T4 (tr) Sübstitüe polisiklik karbamoilpiridon türevi.
BRPI0821255A2 (pt) Derivados de espiroindolinona
UY29373A1 (es) Derivados del 1,5-diarilpirrol, su preparación y su aplicación en terapeutica
MX2012008141A (es) Compuestos y metodos.
UY31688A1 (es) Plaguicidas
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CR10637A (es) Fungicidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.